Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...